Recombinant Proteins and Monoclonal Antibodies

Area of Science:

• Biochemistry
• Molecular Biology
• Immunology

Background:

• Glycoproteins (GPs) constitute a significant portion of human proteins, with their attached oligosaccharide structures critically influencing function.
• These glycoforms are vital for the efficacy, pharmacokinetics, and pharmacodynamics of GP therapeutics, representing a critical quality attribute (CQA).
• Recombinant GP production in non-human cells can lead to structural heterogeneity and the formation of immunogenic glycoforms.

Purpose of the Study:

• To review the significance of glycosylation in recombinant glycoprotein therapeutics.
• To discuss the impact of glycoforms on mechanisms of action (MoAs).
• To explore strategies for developing customized therapeutic glycoforms for optimized efficacy.

Main Methods:

• Literature review focusing on glycoprotein glycosylation.
• Analysis of glycoform impact on therapeutic protein function.
• Discussion of recombinant production platforms and their glycoengineering capabilities.

Main Results:

• Glycosylation is a critical determinant of glycoprotein function and therapeutic efficacy.
• Structural heterogeneity in glycoforms can modulate mechanisms of action (MoAs).
• Non-human expression systems may produce immunogenic glycoforms.

Conclusions:

• Understanding and controlling glycoprotein glycosylation is essential for biopharmaceutical development.
• Customizing glycoforms offers a pathway to enhance therapeutic efficacy and reduce immunogenicity.
• Further research into glycoengineering is crucial for advancing glycoprotein therapeutics.